Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat dyslipidemia or hyperlipidemia. It is recommended to be used with dietary changes, exercise, and weight loss. It is taken orally (by mouth). Common side effects include abdominal pain, nausea, headaches, and muscle pains. Serious side effects may include rhabdomyolysis, liver problems, and diabetes. Use during pregnancy may harm the baby. Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol. Rosuvastatin was patented in 1991 and approved for medical use in the United States in 2003. It is available as a generic medication. In 2023, it was the twelfth most commonly prescribed medication in the United States, with more than 42 million prescriptions. In Australia, it was the most prescribed medication in 2023.
Medical uses
The primary use of rosuvastatin is to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels in the blood.
Effects on cholesterol levels The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses are more effective at improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin. A meta-analysis showed that rosuvastatin can modestly increase the levels of high-density lipoprotein (HDL) cholesterol in the blood, similar to other statins. A 2014 Cochrane review determined there was good evidence for rosuvastatin lowering non-HDL levels linearly with dose.
Side effects and contraindications Side effects are uncommon:
constipation heartburn dizziness sleeplessness depression joint pain cough memory loss or forgetfulness confusion The following rare side effects are more serious. Like all statins, rosuvastatin can possibly cause myopathy, rhabdomyolysis:
muscle pain, tenderness, or weakness lack of energy fever chest pain jaundice: yellowing of the skin or eyes dark colored, or foamy urine pain in the upper right part of the abdomen nausea extreme tiredness weakness unusual bleeding or bruising loss of appetite flu-like symptoms sore throat, chills, or other signs of infection numbness or tingling in fingers or toes (peripheral neuropathy) Allergic reactions can develop:
rash hives itching difficulty breathing or swallowing swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs hoarseness Rosuvastatin has multiple contraindications, including hypersensitivity to rosuvastatin or any component of the formulation, active liver disease, elevation of serum transaminases, pregnancy, or breastfeeding. Rosuvastatin is not prescribed nor used while pregnant, as it can cause serious harm to the fetus. With breastfeeding, it is unknown whether rosuvastatin is passed through breastmilk. Dose adjustments needs to be considered in individuals with renal failure. In mild to moderate renal failure (CLcr >30 to <60 mL/min/1.73 m2) a higher dose than 20mg daily is generally not recommended. Maximum dose of Rosuvastatin in patients with severe renal failure (CLcr < 30 mL/min/1.73 m2) without hemodialysis is 10mg daily. The risk of myopathy may be increased in Asian Americans: "Because Asians appear to process the drug differently, half the standard dose can have the same cholesterol-lowering benefit in those patients, though a full dose could increase the risk of side effects, a study by the drug's manufacturer, AstraZeneca, indicated." Therefore, the lowest dose is recommended in Asians.
Myopathy As with all statins, there is a concern of rhabdomyolysis, a severe undesired side effect. The U.S. Food and Drug Administration (FDA) has indicated that "it does not appear that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has mandated that a warning about this side-effect, as well as a kidney toxicity warning, be added to the product label.
Diabetes mellitus Statins increase the risk of diabetes, consistent with FDA's review, which reported a 27% increase in investigator-reported diabetes mellitus in rosuvastatin-treated people.
Drug interactions The following drugs can have negative interactions with rosuvastatin and should be discussed with the prescribing doctor:
Coumadin anticoagulants ('blood thinners', e.g. warfarin) can affect the removal of rosuvastatin Ciclosporin, colchicine Drugs that may decrease the levels or activity of endogenous steroid hormones, e.g., cimetidine, ketoconazole, and spironolactone Additional medications for high cholesterol such as clofibrate, fenofibrate, gemfibrozil, and niacin (when taken in lipid-modifying doses of 1 g/day and above) Specific protease inhibitors including atazanavir (when taken with ritonavir), lopinavir/ritonavir and simeprevir Alcohol intake should be reduced while on rosuvastatin to decrease the risk of developing liver damage Aluminum and magnesium hydroxide antacids should not be taken within two hours of taking rosuvastatin Coadministration of rosuvastatin with eluxadoline may increase the risk of rhabdomyolysis and myopathy Grapefruit juice negatively interacts with several specific drugs in the statin class, but it has little or no effect on rosuvastatin.
Structure Rosuvastatin has structural similarities with most other statins, e.g., atorvastatin, cerivastatin and pitavastatin, but unlike other statins, rosuvastatin contains sulfur (in sulfonyl functional group). Crestor is a calcium salt of rosuvastatin, i.e., rosuvastatin calcium, in which calcium replaces the hydrogen in the carboxylic acid group on the right of the skeletal formula at the top right of this page.
Mechanism of action
Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins. Putative beneficial effects of rosuvastatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme Q10 levels in patients with chronic heart failure.
… excerpt ends here. Continue reading the full article.




